- Home
- FNLC vs LXEO Comparison
FNLC vs LXEO Comparison
Compare FNLC & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FNLC | LXEO |
|---|---|---|
| Founded | 1864 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.5M | 387.1M |
| IPO Year | 1995 | 2023 |
Fundamental Metrics
Financial Performance| Metric | FNLC | LXEO |
|---|---|---|
| Price | $34.60 | $4.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | 25.7K | ★ 803.0K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | 26.34 | ★ 39.81 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.13 | $3.60 |
| 52 Week High | $34.50 | $10.99 |
Technical Indicators
Market Signals| Indicator | FNLC | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 80.68 | 47.57 |
| Support Level | $28.08 | $4.44 |
| Resistance Level | N/A | $5.34 |
| Average True Range (ATR) | 1.30 | 0.35 |
| MACD | 0.53 | 0.08 |
| Stochastic Oscillator | 99.01 | 57.25 |
Price Performance
Historical ComparisonAbout FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services, including deposit accounts and consumer, commercial, and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.